Cetuximab-related skin toxicity and efficacy: do we understand the mechanisms?
- 12 May 2020
- journal article
- letter
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (7), 964-965
- https://doi.org/10.1016/j.annonc.2020.03.301
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)Annals of Oncology, 2020
- Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patientsBritish Journal of Clinical Pharmacology, 2019
- Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulationCancer Treatment Reviews, 2017
- Pharmacogenetic Profiling for Cetuximab Plus Irinotecan Therapy in Patients With Refractory Advanced Colorectal CancerJournal of Clinical Oncology, 2008
- An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor InhibitorsCancer Research, 2004